substrate reduction therapy

https://pompediseasenews.com/news/substrate-reduction-therapy-abx1100-fda-orphan-drug-status/ Substrate Reduction Therapy ABX1100 Granted FDA Orphan Drug Status | Pompe Disease News Aug 11, 2022 - ABX1100, Aro Biotherapeutics' experimental substrate reduction therapy for Pompe disease, has been granted orphan drug status by the FDA. substrate reduction therapy orphan drug status pompe disease granted fda

Robuta